Get the Stockscreener App
1.65
3.12%
0.05
Sana Biotechnology Inc stock is traded at $1.65, with a volume of 3.09M.
It is up +3.12% in the last 24 hours and down -34.78% over the past month.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.
See More
Previous Close:
$1.60
Open:
$1.59
24h Volume:
3.09M
Relative Volume:
1.88
Market Cap:
$368.39M
Revenue:
-
Net Income/Loss:
$-283.26M
P/E Ratio:
-0.873
EPS:
-1.89
Net Cash Flow:
$-273.61M
1W Performance:
-12.70%
1M Performance:
-34.78%
6M Performance:
-68.45%
1Y Performance:
-59.76%
1-Day Range:
$1.55
$1.72
1-Week Range:
$1.55
$2.07
52-Week Range:
$1.55
$12.00
Sana Biotechnology Inc Stock (SANA) Company Profile
Name
Sana Biotechnology Inc
Sector
Industry
Phone
(206) 701-7914
Address
188 EAST BLAINE STREET, SUITE 400, SEATTLE
Compare SANA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
1.65 | 368.39M | 0 | -283.26M | -273.61M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-26-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-25-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Aug-14-23 | Initiated | TD Cowen | Market Perform |
| May-02-23 | Initiated | H.C. Wainwright | Neutral |
| Mar-01-21 | Initiated | BofA Securities | Buy |
| Mar-01-21 | Initiated | Goldman | Neutral |
| Mar-01-21 | Initiated | JP Morgan | Neutral |
| Mar-01-21 | Initiated | Morgan Stanley | Overweight |
View All
Sana Biotechnology Inc Stock (SANA) Latest News
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Sana Biotechnology stock hits 52-week low at $1.8 amid downturn - Investing.com Canada
Layoff Tracker: Editas Will Cut 60% of Staff - BioSpace
Sana Biotechnology's SWOT analysis: cell therapy stock faces pivotal year ahead - Investing.com Canada
Sana Biotechnology stock hits 52-week low at $2.29 By Investing.com - Investing.com Canada
Sana Biotechnology stock hits 52-week low at $2.29 - Investing.com
Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus - Seeking Alpha
Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Bought by Fmr LLC - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc.SANA - PR Newswire
Sana Biotechnology Gets FDA Fast Track Designation for SC291 Cell Therapy - MarketWatch
Sana Biotechnology announces Fast Track designation for SC291 - TipRanks
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic - The Bakersfield Californian
Sana Biotechnology Announces Fast Track Designation for - GlobeNewswire
Sana Biotechnology (NASDAQ:SANA) Trading 9.8% HigherStill a Buy? - MarketBeat
Sana Biotechnology's (SANA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Sana Biotechnology to Present at December 2024 Investor Conferences - The Manila Times
Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies - Quantisnow
Sana Biotechnology: The Story Becomes Murkier (NASDAQ:SANA) - Seeking Alpha
Sana Biotechnology (NASDAQ:SANA) Sets New 12-Month LowShould You Sell? - MarketBeat
10 Stocks Jeff Bezos Is Buying | Investing - U.S News & World Report Money
Sana Biotechnology's SWOT analysis: stock outlook amid strategic pivot - Investing.com India
Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio - Quantisnow
Sana Biotechnology, Inc. (NASDAQ:SANA) Holdings Lowered by Baillie Gifford & Co. - MarketBeat
Sana Biotechnology stock hits 52-week low at $2.75 By Investing.com - Investing.com Australia
FMR LLC's Strategic Acquisition of Sana Biotechnology Inc Shares - GuruFocus.com
Sana Biotechnology stock hits 52-week low at $2.75 - Investing.com India
Sana Biotech sustains stock target with Buy rating on Q3 earnings - Investing.com Nigeria
Analyst keeps Buy on Sana Biotechnology, adjusts outlook as blood cancer competition rises - Investing.com Canada
Sana Biotechnology's SWOT analysis: stock outlook amid strategic pivot By Investing.com - Investing.com Nigeria
Sana Biotechnology (NASDAQ:SANA) Hits New 1-Year LowWhat's Next? - MarketBeat
Sana Biotechnology Inc Still Hasn’t Convinced Analysts? - Stocks Register
HC Wainwright Reaffirms "Buy" Rating for Sana Biotechnology (NASDAQ:SANA) - MarketBeat
Sana Biotechnology downgraded to Market Perform from Outperform at JMP Securities - MSN
Sana Biotechnology, Inc. Reports Q3 2024 Financial Results - TipRanks
Sana: Q3 Earnings Snapshot - The Washington Post
Sana Biotechnology Inc. (SANA) Quarterly 10-Q Report - Quartzy
Earnings Flash (SANA) SANA BIOTECHNOLOGY Reports Q3 Loss $-0.27 Per Share - Marketscreener.com
Sana Biotechnology Inc Stock (SANA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):